1J in Z, Zhang WX,Chen B,et al. Stepwise regression analysis of the determinants of blood tacrolimus concentrations in Chinese patients with liver transplant[J]. Med Chem,2009,5(3): 301- 304.
1Zhu B,Chen GL,Chen XP,et al.Genotype of CYP3AP1 associated with CYP3A activity in Chinese H an population[J].Acta Pharmacol Sin,2002,23(60):567.
2Paulussen A,Lavrijsen K,Bohents H,et al.Two linked mutations in tuanscriptional regulatory.elements of the CYP3A5 gene constitute the.major genetic determinant of polymorphic activity in humans[J].Pharmacogenetics,2000,10(5):415.
3Hoffmeyer S,Burk O,Von RO,et al.Functional polymorphisms of the human multidrug resistance gene:multiple sequence variations and correlation of one allele with P-glycoprote in expression and activity in vivo[J].Proc Natl Acad Sci USA,2000,97(7):3 473.
4.
5.
6.
7.
8Padhi ID,Long P,Basha M,et al.Interaction between tacrolimus and erythromycin[J].Ther Drug Monit,1997,19(1):120.
9Schulman SL,Shaw LM,Jabs K,et al.Interaction between tacrolimus and chlora mphenicd in a renal transplant recipient[J].Transplantation,1998,65(10):1 397.
3Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants[J]. Pharmacotherapy, 2006, 26(12), 1730-1744.
4Tintillier M, Kirch L, Goffin E, et al. Interaction between vorieonazole and tacrolimus in a kidney, transplanted patient[J]. Nephrol Dial Transplant, 2005, 20(3): 664-665.
5Chang HH, Lee NY, Ko WC, et al. Voriconazole inhibition of metabolism in a kidney transplant recipient with fluconazole-resistant cryptococcal meningitis[J]. Int J Infect Dis. 2010, 14(4): e348-350.
6Capone D, Tarantino G, Gentile A, et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient[J]. J Clin Pharrn Ther, 2010, 35(1): 121-124.
7Guy-Viterbo V, Scohy A, Verbeeck RK, et al. Population pharmacokinetic analysis of tacrolimus in the first year after pediatric liver transplantation[J]. Eur J Clin Pharmacol, 2013, 69(8) : 1533-1542.
8Yano I, Masuda S, Egawa H, et al. Significance of troughmonitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation[J]. Eur J Clin Pharmacol, 2012, 68(3): 259- 266.
9Durand P, Debray D, Kolaci M, et al. Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism. Pharmacogenomics, 2(}13, 14 (9) : 1017-1025.
10Ji E, Choi L, Suh KS,et al. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation,2012,94(8) : 866-872.
